Determination of Drug Levels for Pharmacotherapy of Heart Failure

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Cardiovascular DiseasesHeart Failure With Reduced Ejection Fraction
Interventions
DRUG

Nebivolol

Nebivolol (Nebilet) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.

DRUG

Valsartan and Sacubitril

Valsartan and Sacubitril (Entresto) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.

DRUG

Carvedilol

Carvedilol (Dilatrend) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.

DRUG

Bisoprolol

Bisoprolol (Concor) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.

DRUG

Metoprolol

Metoprolol (Betaloc ZOK) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.

DRUG

Spironolactone

Verospiron (Spironolactone) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.

Trial Locations (1)

70852

University Hospital Ostrava, Ostrava

All Listed Sponsors
lead

University Hospital Ostrava

OTHER